ArcticZymes Technologies ASA B4V
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €1.74
- Day Range
- €1.76–1.78
- 52-Week Range
- —–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 51.07M
- Market Cap
- NOK 90.65M
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 67.26
- Price/Sales
- 8.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 59
- Website
- https://www.arcticzymes.com
Valuation
|
Metric
|
B4V
|
|---|---|
Price/Earnings (Normalized) | 67.26 |
Price/Book Value | 2.91 |
Price/Sales | 8.20 |
Price/Cash Flow | 31.17 |
Price/Earnings
B4V
Financial Strength
|
Metric
|
B4V
|
|---|---|
Quick Ratio | 16.67 |
Current Ratio | 17.68 |
Interest Coverage | — |
Quick Ratio
B4V
Profitability
|
Metric
|
B4V
|
|---|---|
Return on Assets (Normalized) | 5.56% |
Return on Equity (Normalized) | 6.01% |
Return on Invested Capital (Normalized) | 3.97% |
Return on Assets
B4V
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#mVT>&< | LOCK|rfd>< | $127B | |||
| Moderna Inc
MRNA
| LOCK|ylK&>f& | LOCK|!Sf | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|dq%L^?L | LOCK|p>@C> | $81B | |||
| argenx SE ADR
ARGX
| LOCK|!P&PbR? | LOCK|X> | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>?dZp% | LOCK|l# | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#%M%@Hr | LOCK|l@$N | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&&Y&L>#z | LOCK|&j&r | $27B | |||
| Incyte Corp
INCY
| LOCK|<^<l!g | LOCK|p# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#!g^!&% | LOCK|>& | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&%l>!zt | LOCK|z& | $14B |
United States